Member Info for Jarv55

Can't say I am a fan of Docs but think he is going to want more than 10% seeing as he bought at 0.25

Sapphire think its the potential of it being a clean shell.

Think they have more than 600k need to check that

Placing was at 25

Current market cap 800k

Bought a few here listing alone has to be worth 500k plus cash in the bank. Few deals being bandied about and the Stevenson upping his holdings, can't be that long before news.

They must be working on a license deal then to mention comercialisation.

Steve Franklin, CEO of Evgen Pharma, said: ''We are delighted by the grant of this core patent in Europe, which further expands our intellectual property position and complements similar grants in the USA, Canada and Australia. This patent grant is timely from a commercial perspective as we are moving close to the announcement of our first Phase II clinical data from SFX-01, which we continue to expect in the first half of this year as part of our ongoing STEM trial in breast cancer."

Fundraiser totally understand when you have researched a stock inside out it can be frustrating when someone posts info that is a cut and paste but that is how most folk research I know I do, If I have a longer term interest I read all the bbs first. Gives me an insight into sentiment. To make it clear I will be trading this, peaks and troughs no point me learning to chart if I didn't. Appreciate all your efforts in the research area it does help me decide whether to stay long term or not but we all trade differently that is what makes a market.

Great consolidation going on to build up strength for the push up, 8ema and 3ema cross, double bottom bounce something is going on here. https://invst.ly/7bpue

Highlights � Successful IPO to the London Stock Exchange � The loss for the interim period was �249,962, including the listing costs of �78,617 � Net assets as at 28 February 2018 were �366,192 Gobind Sahney, Executive Chairman commented: "We are now focused on expanding the Company's operations and following through on the strategy of generating revenues. Since the IPO the Board have been very active in rolling out its current product offerings and is in negotiations with a range of clients and entities, some of which are at an advanced stage, which we hope to announce shortly. Furthermore, we plan to make personnel announcements that will bring a wealth of experience, relationships, and validate the Company's business plan in the near term. I would like to take this opportunity to thank the shareholders for their continued support and work with us to build a company for the long term."

Well that pulled back up a lot quicker than I thought it would bull flag forming on the hourly

Viera point me in the direction of the twitter ramp please because I am on twitter and I must of missed it.

https://www.**********.co.uk/blogs/nic-charts-evgen-evg-evr-holdings-evrh-feedback-fdbk-ncondezi-energy-nccl-sunrise-resources-sres/

On the technical side this could fall back to 15

Does look very interesting https://www.youtube.com/watch?v=vloQ-N-D8sY&feature=youtu.be

Tech trader first then if I like it I will add to my positions always scale in.

Fundraiser just bought in what have you got give me the fundamentals here might save me a bit of time.

http://www.proactiveinvestors.co.uk/columns/northland-capital-partners-view-on-the-city/29626/northland-capital-partners-view-on-the-city-evgen-pharma-lonevg-alexander-mining-lonasm-n4-pharma-lonn4p-29626.html

Phase 2 trial �STEM� in metastatic breast cancer: With 18 out of the 60 patients in the trial having been dosed as of December 2017, an interim read-out is expected this quarter followed by final topline results in H2�2018E. A compassionate use programme, which allows patients to stay on the drug post trial end, has already been implemented.